1. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAFV600E papillary thyroid carcinoma cells confers resistance to BRAF inhibitor vemurafenib
   Nianxue Wang et al, 2021, Cancer Chemotherapy and Pharmacology CrossRef
2. RFWD2 Knockdown as a Blocker to Reverse the Oncogenic Role of TRIB2 in Lung Adenocarcinoma
   Ruimin Hao et al, 2021, Frontiers in Oncology CrossRef